154455-57-9

Usage

Uses

Used in Pharmaceutical Industry:
(E)-1, 2-dichloro-3-(2-nitrovinyl)benzene is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique structure allows for the creation of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Within the agrochemical industry, (E)-1, 2-dichloro-3-(2-nitrovinyl)benzene is utilized as a key component in the synthesis of pesticides and other agrochemical products, contributing to enhanced crop protection strategies.
Used in Dye Production:
(E)-1, 2-dichloro-3-(2-nitrovinyl)benzene is used as a building block in the production of dyes, where its chemical properties are leveraged to create a range of colorants for various applications.
Used in Pigment Manufacturing:
(E)-1, 2-dichloro-3-(2-nitrovinyl)benzene is also employed in the manufacturing of pigments, where its chemical structure contributes to the development of pigments with specific color and stability characteristics.
Used in Polymer Production:
(E)-1, 2-dichloro-3-(2-nitrovinyl)benzene is used as a monomer in the production of polymers, playing a significant role in determining the polymer's properties and potential applications.

Upstream product

• 75-52-5 nitromethane 
• 6334-18-5 2,3-dichlorobenzylaldehyde 

Downstream Products

• 1610555-42-4 (R)-3-[1-(2,3-dichloro-phenyl)-2-nitro-ethyl]-pentane-2,4-dione 
• 1378976-06-7 4-(2,3-dichlorophenyl)-1H-1,2,3-triazole 
• 1424329-32-7 5-exo-(2,3-dichlorophenyl)-6-endo-nitrobicyclo[2.2.1]hept-2-ene 

Relevant academic research and scientific papers

Dipolar HCP materials as alternatives to DMF solvent for azide-based synthesis

Hypercrosslinked polymers HCP-DMF and HCP-DMF-SO3H containing abundant and flexible DMF moieties were designed and synthesized. Benefitting from the solvation microenvironment provided by the pseudo-DMF moities, the polar HCPs manifested outstanding performances in the conversions of NaN3 to benzylic azides and 1,2,3-triazoles in EtOH (95%), respectively, avoiding the use of risky DMF and improving the separation processes of the products.

Catalytic and Mechanistic Developments of the Nickel(II) Pincer Complex-Catalyzed Hydroarsination Reaction

Synthetic challenges have significantly slowed the development of the catalytic asymmetric hydroarsination reaction despite it being a highly attractive C?As bond formation methodology. In addition, there is a poor understanding of the main reaction steps in such reactions which limit further development in the field. Herein, key intermediates of the hydroarsination reaction catalyzed by a PCP NiII-Cl pincer complex are presented upon investigating the reaction with DFT calculations, conductivity measurements, NMR spectroscopy, and catalytic screening. The novel Ni–Cl–As interaction proposed was then contrasted against known NiII-catalyzed hydrophosphination reactions to highlight dissimilarities between them even though P and As share a close group relationship. Lastly, the asymmetric hydroarsination of nitroolefins was further developed to furnish a library of chiral organoarsines in up to 99 % yield and 80 % ee under mild conditions (?20 °C to RT) between 5 to 210 mins.

BETA-NITROSTYRENE COMPOUND AND TELOMERASE INHIBITOR HAVING AN ANTICANCER ACTIVITY

The present invention relates to beta-nitrostyrene compounds, and pharmaceutically acceptable salts and hydrates thereof having the following formula (I) and showing anticancer activity. Formula (I) wherein R1 to R5 are each independently any one selected from the group consisting of hydrogen, halogen, halogenated phenoxy and a radical of R6-Y-X- (-X- is -O- or -NH-, -Y- is -SO2-or -CO-, R6 is benzene substituted with at least any one selected from the group consisting of hydrogen, alkyl, halogen and NO2), or R3 forms a benzene ring along with R4; provided that R1, R2, R3, R4 and R5 are not hydrogen at the same time. These compounds can selectively inhibit the activity of telomerase specifically expressed in cancer cells and thus be used as an anticancer with minimized side effects of the conventional anticancer agents.